Technology and the issue of cost/benefit in diabetes

Diabetes/Metabolism Research and Reviews

Volumn 25, Issue SUPPL. 1, 2009, Pages

  Giannini, Cosimo ^a   Mohn, Angelika ^a   Chiarelli, Francesco ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Cost effectiveness; CSII; Insulin analogues; Technology; Type 1 diabetes; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; RECOMBINANT HUMAN INSULIN;

BLOOD GLUCOSE MONITORING; BLOOD PRESSURE MONITORING; CONFERENCE PAPER; CONTINUOUS INFUSION; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIABETIC FOOT; DIABETIC KETOACIDOSIS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ECONOMIC ASPECT; GLYCEMIC CONTROL; HEALTH CARE COST; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; LIFE EXPECTANCY; LIPID ANALYSIS; METABOLIC REGULATION; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; PHARMACOECONOMICS; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; SELF ESTEEM; SENSITIVITY ANALYSIS; SOCIOECONOMICS; STROKE;

ADOLESCENT; ADULT; AGED; BIOTECHNOLOGY; BLOOD GLUCOSE SELF-MONITORING; CHEMISTRY, PHARMACEUTICAL; CHILD; COST OF ILLNESS; COSTS AND COST ANALYSIS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HEALTH CARE COSTS; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; MIDDLE AGED; PREVALENCE; RECOMBINANT PROTEINS; WORLD HEALTH; YOUNG ADULT;

EID: 73349104925     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.986     Document Type: Conference Paper

References (72)

1. International Diabetes Federation (IDF). World Atlas of Diabetes. Executive Summary (2nd edn). International Diabetes Federation (IDF): 2008; available from www.eatlas.idf.org) [21 October 2008].
2. Aanstoot HJ, Anderson BJ, Daneman D, et al. Diabetes in children: epidemiology. Pediatr Diabetes 2007; 8(Suppl. 8): 10-18.
3. Soltesz G, Patterson CC, Dahlquist G.Worldwide childhood type 1 diabetes incidence - - what can we learn from epidemiology? Pediatr Diabetes 2007; 8: 6-14.
4. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21(9): 1414-1431.
5. Pihoker C, Scott CR, Lensing SY, Cradock MM, Smith J. Noninsulin dependent diabetes mellitus in African-American youths of Arkansas. Clin Pediatr (Phila) 1998; 37(2): 97-102.
6. Drake AJ, Smith A, Betts PR, Crowne EC, Shield JP. Type 2 diabetes in obese white children. Arch Dis Child 2002; 86(3): 207-208.
7. Kitagawa T, Owada M, Urakami T, Yamauchi K. Increased incidence of non-insulin dependent diabetes mellitus among Japanese schoolchildren correlates with an increased intake of animal protein and fat. Clin Pediatr (Phila) 1998; 37(2): 111-115.
8. Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 2003; 26(3): 917-932.
9. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008; 31(3): 596-615.
10. American Diabetes Association. Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 1998; 21(2): 296-309.
11. Ettaro L, Songer TJ, Zhang P, Engelgau MM. Cost-of-illness studies in diabetes mellitus. Pharmacoeconomics 2004; 22(3): 149-164.
12. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276(16): 1339-1341.
13. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276(15): 1253-1258.
14. Ray JA, Valentine WJ, Secnik K, et al. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain. Curr Med Res Opin 2005; 21(10): 1617-1629.
15. Gray A, Fenn P, McGuire A. The cost of insulin-dependent diabetes mellitus (IDDM) in England and Wales. Diabet Med 1995; 12(12): 1068-1076.
16. Henriksson F, Jonsson B. Diabetes: the cost of illness in Sweden. J Intern Med 1998; 244(6): 461-468.
17. Holmes J, Gear E, Bottomley J, Gillam S,Murphy M,Williams R. Do people with type 2 diabetes and their carers lose income? (T2ARDIS-4). Health Policy 2003; 64(3): 291-296.
18. Gilliland FD, Berhane K, Islam T, et al. Environmental tobacco smoke and absenteeism related to respiratory illness in schoolchildren. Am J Epidemiol 2003; 157(10): 861-869.
19. Kearney CA, Sims KE, Pursell CR, Tillotson CA. Separation anxiety disorder in young children: a longitudinal and family analysis. J Clin Child Adolesc Psychol 2003; 32(4): 593-598.
20. Breuner CC, Smith MS, Womack WM. Factors related to school absenteeism in adolescents with recurrent headache. Headache 2004; 44(3): 217-222.
21. Ceci S, Williams W. Schooling, intelligence, and income. Am Psychol 1997; 52: 1051-1058.
22. Wolbers M. The effects of level of education onmobility between employment and unemployment in the Netherlands. Eur Sociol Rev 2000; 16: 185-200.
23. McQuaid R, Lindsay C. The concept of employability. Urban Stud 2005; 42: 197-219.
24. Milton B, Holland P, Whitehead M. The social and economic consequences of childhood-onset Type 1 diabetes mellitus across the lifecourse: a systematic review. Diabet Med 2006; 23: 821-829.
25. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl JMed 1993; 329(14): 977-986.
26. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on themicrovascular complications of type 1 diabetes mellitus. JAMA 2002; 287(19): 2563-2569.
27. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837-853.
28. Diabetes Control and Complications Trial Research Group. Lifetime benefits of intensive therapy as practiced in the Diabetes Control and Complications Trial. JAMA 1996; 276: 1409-1415.
29. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26(3): 881-885.
30. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22(8): 1385-1387.
31. Stern Z, Levy R. Analysis of direct cost of standard compared with intensive insulin treatment of insulin-dependent diabetes mellitus and cost of complications. Acta Diabetol 1996; 33: 48-52.
32. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of Analysis of the health benefits and costeffectiveness of t reating NIDDM with the goal of norm oglycemia. Diabetes Care 1997; 20: 735-744.
33. Gilmer TP, O'Connor PJ, Rush WA, et al. Predictors of health care costs in adults with diabetes. Diabetes Care 2005; 28: 59-64.
34. Danne T, Mortensen HB, Hougaard P, et al.; for the Hvidøre Study Group. On Childhood Diabetes Persistent Differences Among Centers Over 3 Years in Glycemic Control and Hypoglycemia in a Study of 3,805 Children and Adolescents With Type 1 Diabetes From the Hvidøre Study Group. Diabetes Care 2001; 24: 1342-1347.
35. Shalitin S, Phillip M. The role of new technologies in treating children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes 2007; 8(Suppl. 6): 72-79.
36. Stephens E, Riddle M. Evolving approaches to intensive insulin therapy in type 1 diabetes: multiple daily injections, insulin pumps and new methods of monitoring. Rev Endocr Metab Disord 2003; 4: 325-334.
37. Gough S. A review of human and analogue insulin trials. Diabetes Res Clin Pract 2007; 77: 1-15.
38. Reviriego J, Gomis R, Maran JP, Ricart W, Hudson P, Sacrista JA. Cost of severe hypoglycaemia in patients with type 1 diabetes in Spain and the cost-effectiveness of insulin lispro compared with regular human insulin in preventing severe hypoglycaemia. Int J Clin Pract 2008; 62(7): 1026-1032.
39. Anderson JH Jr, Brunelle RL, Koivisto VA, et al. Multicenter Insulin Lispro Study Group. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulinanalog treatment. Diabetes 1997; 46: 265-270.
40. Minshall ME, Twena NS, Nicklasson L, et al. Long-term costeffectiveness of insulin aspart versus soluble human insulin in patients with type-1 diabetes in the United Kingdom. Value Health 2003; 8: 358-359.
41. Palmer AJ, Roze S, Valentine WJ, et al. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type-1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials. Curr Med Res Opin 2004; 20: 1729-1746.
42. Palmer WJ, Valentine A, Joshua A, et al. An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK. Curr Med Res Opin 2007; 23: 895-901.
43. McEwan P, Poole CD, Tetlow T. Evaluation of the costeffectiveness of insulin glargine versus NPH insulin for the treatment of type-1 diabetes in the UK. Current Medical Research and Opinion 2007; 23(1): S7-S19.
44. Colquitt JL, Green C, Sidhu MK, Hartwell D, Waugh N. Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes. Health Technol Assess 2004; 8(43): iii, 1-171.
45. Grima DT, Thompson MF, Odelling LS. Cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada. Pharmacoeconomics 2007; 25(3): 253-266.
46. McEwan P, Poole CD, Tetlow T. Evaluation of the costeffectiveness of insulin glargine versus NPH insulin for the treatment of type-2 diabetes in the UK. Current Medical Research and Opinion 2007; 23(1): S21-S31.
47. Valentine WJ, Palmer AJ, Erny-Albrecht KM, et al. Costeffectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH. Adv Ther 2006; 23(2): 191-207.
48. Jeitler K, Horvath K, Berghold A, et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and metaanalysis. Diabetologia 2008; 51(6): 941-951.
49. Tamborlane WV, Sikes KA, Steffen AT, Weinzimer SA. Continuous subcutaneous insulin infusion (CSII) in children with type 1 diabetes. Diabetes Res Clin Pract 2006; 74(Suppl. 2): S112-S115.
50. Battelino T. Risk and benefits of continuous subcutaneous insulin infusion (CSII) treatment in school children and adolescents. Pediatr Diabetes 2006; 7(Suppl. 4): 20-24.
51. Radermecker RP, Scheen AJ. Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness. Diabetes Metab Res Rev 2004; 20(3): 178-188.
52. Nuboer R, Bruining GJ. Cost-effectiveness of continuous subcutaneous insulin infusion (CSII) in children: illusion or delusion? Pediatr Diabetes 2006; 7(Suppl. 4): 39-44.
53. Roze S, Valentine WJ, Zakrzewska KE, Palmer AJ. Healtheconomic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK. Diabet Med 2005; 22(9): 1239-1245.
54. Cohen N, Minshall ME, Sharon-Nash L, Zakrzewska K, Valentine WJ, Palmer AJ. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia. Pharmacoeconomics 2007; 25(10): 881-897.
55. Haller MJ, Stalvey MS, Silverstein JH. Predictors of control of diabetes: monitoring may be the key. J Pediatr 2004; 144(5): 660-661.
56. Schutt M, Kern W, Krause U, et al. Is the frequency of selfmonitoring of blood glucose related to long-term metabolic control? Multicenter analysis including 24,500 patients from 191 centers in Germany and Austria. Exp Clin Endocrinol Diabetes 2006; 114(7): 384-388.
57. Karter AJ, Ackerson LM, Darbinian JA, et al. Self-monitoring of blood glucose levels and glycemic control: the Northern California kaiser permanente diabetes registry. Am J Med 2001; 111: 1-9.
58. Evans JM, Newton RW, Ruta DA, MacDonald TM, Stevenson RJ, Morris AD. Frequency of blood glucose monitoring in relation to glycaemic control: observational study with diabetes database. Br Med J 1999; 319(7202): 83-86.
59. Bode BW, Gross TM, Thornton KR, Mastrototaro JJ. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. Diabetes Res Clin Pract 1999; 46(3): 183-190.
60. Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. Pediatrics 2003; 111(5 Pt 1): 933-838.
61. Garg S, Jovanovic L. Relationship of fasting and hourly blood glucose levels to HbA1c values: safety, accuracy, and improvements in glucose profiles obtained using a 7-day continuous glucose sensor. Diabetes Care 2006; 29(12): 2644-2649.
62. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Tamborlane WV, Beck RW, Bode BW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl JMed 2008; 359(14): 1464-1476.
63. Chase HP, Roberts MD, Wightman C, et al. Use of the GlucoWatch biographer in children with type 1 diabetes. Pediatrics 2003; 111(4 Pt 1): 790-794.
64. Diabetes Research in Children Network (DirecNet) Study Group. Youth and parent satisfaction with clinical use of the GlucoWatch G2 Biographer in the management of pediatric type 1 diabetes. Diabetes Care 2005; 28(8): 1929-1935.
65. Garg SK, Smith J, Beatson C, Lopez-Baca B, Voelmle M, Gottlieb PA. Comparison of Accuracy and Safety of the SEVEN and the Navigator Continuous Glucose Monitoring Systems. Diabetes Technol Ther 2009; 11(2): 65-72.
66. Pacaud D, Lemay JF, Buithieu M, Yale JF. Blood volumes and pain following capillary punctures in children and adolescents with diabetes. Diabetes Care 1999; 22(9): 1592-1594.
67. Burge MR. Lack of compliance with home blood glucose monitoring predicts hospitalization in diabetes. Diabetes Care 2001; 24(8): 1502-1503.
68. Nyomba BL, Berard L, Murphy LJ. The cost of self-monitoring of blood glucose is an important factor limiting glycemic control in diabetic patients. Diabetes Care 2002; 25(7): 1244-1245.
69. Bu D, Pan E, Walker J, et al. Benefits of information technologyenabled diabetes management. Diabetes Care 2007; 30(5): 1137-1142.
70. Eastman RC, Leptien AD, Chase HP. Cost-effectiveness of use of the GlucoWatch Biographer in children and adolescents with type 1 diabetes: a preliminary analysis based on a randomized controlled trial. Pediatr Diabetes 2003; 4(2): 82-86.
71. Sachedina N, Pickup JC. Performance assessment of the Medtronic-MiniMed Continuous Glucose Monitoring System and its use for measurement of glycaemic control in Type 1 diabetic subjects. Diabet Med 2003; 20(12): 1012-1015.
72. Cameron FJ, Ambler GR. Does continuous glucose monitoring have clinical utility in contemporary management of diabetes?. J Paediatr Child Health 2004; 40(3): 79-84.